Adagloxad Simolenin (OBI-822)/OBI-821, receives a positive 1st interim analysis recommendation, suggesting the continuation of the Phase III TNBC trial

1.Date of occurrence of the event:2024/01/31 2.New drug name or code: The active cancer immunotherapy Adagloxad Simolenin (OBI-822)/OBI-821 3.Indication: Adagloxad Simolenin (OBI-822) is a therapeutic cancer vaccine classified as an active cancer immunotherapy. Globo H-KLH conjugate triggers immune response against hard-to-treat cancers once injected into the human system. OBI-821 is an adjuvant that is mixed […]

This article is password protected.

To view the content, please enter your password in the field below